

IgD, Native Human IgD Myeloma Plasma

Catalog No.	CSI19839A	Quantity:	100 µg
	CSI19839B		0.5 mg

Description: IgD was first identified in 1965, and like other immunoglobulins, exists as both secreted and membrane forms. Its level in plasma is low with a mean concentration of 30 ug/ml. IgD is present in large quantities on the surface membrane of a majority of human circulating B lymphocytes. IgD enhances humoral immune responses through its induction of IgD-receptor expression on T lymphocytes. Ref.: Coico RF, Siskind GW, Thorbecke GJ 1988. Immunol. Rev. 105:45. Prepared from myeloma plasma shown to be non reactive for HbsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests. >95 percent pure by SDS-PAGE.

Concentration: 1.0 mg/ml

Source: Human myeloma plasma

Molecular Weight: 185,000

Formulation: Liquid in 0.01M Tris-HCl + 0.15M NaCl + 0.01M EACA, 0.05% Azide; pH 8.0

Purity: >95% by SDS-PAGE analysis

Application Notes: The optimal concentration should be determined by the user for each specific application.

Storage & Stability: When stored at -80°C, product is stable for 3 years from date of delivery.

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.